Capricor Therapeutics Presents New Data From Ongoing HOPE-3 OLE Study For Its Lead Asset, Deramiocel, For Treatment Of Upper Limb Impairment In DMD, At 31st Annual Congress Of WMS In Hiroshima

-24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year-

-At 24 Months, Both Groups Showed Slower Decline in Upper Limb Function Than Natural History Predicts-

-Data Included in Deramiocel BLA Major Amendment; PDUFA Target Action Date November 22, 2026-

-Webinar Scheduled for October 7, 2026, at 1:00 p.m. ET in Collaboration with PPMD to Discuss the Data-

SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive new data from its ongoing HOPE-3 open-label extension (OLE) study for its lead asset, Deramiocel, for the treatment of upper limb impairment in Duchenne muscular dystrophy (DMD). The data were highlighted in a late-breaking poster presentation at the 31st Annual Congress of the World Muscle Society (WMS) in Hiroshima, Japan, supporting HOPE-3’s previously reported 12-month results, which were also presented in a separate oral session on Deramiocel's musculoskeletal and cardiac efficacy.